These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33612048)

  • 21. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
    Kennedy SH; Lam RW; McIntyre RS; Tourjman SV; Bhat V; Blier P; Hasnain M; Jollant F; Levitt AJ; MacQueen GM; McInerney SJ; McIntosh D; Milev RV; Müller DJ; Parikh SV; Pearson NL; Ravindran AV; Uher R;
    Can J Psychiatry; 2016 Sep; 61(9):540-60. PubMed ID: 27486148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis.
    Galling B; Calsina Ferrer A; Abi Zeid Daou M; Sangroula D; Hagi K; Correll CU
    Expert Opin Drug Saf; 2015 Oct; 14(10):1587-608. PubMed ID: 26360500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bright Light Therapy as Augmentation of Pharmacotherapy for Treatment of Depression: A Systematic Review and Meta-Analysis.
    Penders TM; Stanciu CN; Schoemann AM; Ninan PT; Bloch R; Saeed SA
    Prim Care Companion CNS Disord; 2016 Oct; 18(5):. PubMed ID: 27835725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
    Goss AJ; Kaser M; Costafreda SG; Sahakian BJ; Fu CH
    J Clin Psychiatry; 2013 Nov; 74(11):1101-7. PubMed ID: 24330897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solving the antidepressant efficacy question: effect sizes in major depressive disorder.
    Vöhringer PA; Ghaemi SN
    Clin Ther; 2011 Dec; 33(12):B49-61. PubMed ID: 22136980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early switching strategies in antidepressant non-responders: current evidence and future research directions.
    Kudlow PA; McIntyre RS; Lam RW
    CNS Drugs; 2014 Jul; 28(7):601-9. PubMed ID: 24831418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial.
    Manber R; Buysse DJ; Edinger J; Krystal A; Luther JF; Wisniewski SR; Trockel M; Kraemer HC; Thase ME
    J Clin Psychiatry; 2016 Oct; 77(10):e1316-e1323. PubMed ID: 27788313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized Treatment Strategy for Depressive Disorder.
    Chen P
    Adv Exp Med Biol; 2019; 1180():201-217. PubMed ID: 31784965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
    Papakostas GI; Martinson MA; Fava M; Iovieno N
    J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder.
    Cha DS; Luo X; Ahmed J; Becirovic L; Cha RH; McIntyre RS
    Expert Rev Neurother; 2019 Sep; 19(9):777-783. PubMed ID: 31389279
    [No Abstract]   [Full Text] [Related]  

  • 34. Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature.
    Cosci F; Mansueto G; Fava GA
    Int J Psychiatry Clin Pract; 2020 Nov; 24(4):341-348. PubMed ID: 32716222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder.
    Cameron IM; Reid IC; MacGillivray SA
    J Affect Disord; 2014 Sep; 166():48-58. PubMed ID: 25012410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines.
    Bauer M; Severus E; Möller HJ; Young AH;
    Int J Psychiatry Clin Pract; 2017 Sep; 21(3):166-176. PubMed ID: 28367707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic.
    Papakostas GI; Petersen TJ; Green C; Iosifescu DV; Yeung AS; Nierenberg AA; Fava M; Posternak MA
    Ann Clin Psychiatry; 2005; 17(3):161-5. PubMed ID: 16433058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
    Davis LL; Pilkinton P; Wisniewski SR; Trivedi MH; Gaynes BN; Howland RH; Zisook S; Balasubramani GK; Fava M; Rush AJ
    Depress Anxiety; 2012 Feb; 29(2):111-22. PubMed ID: 22495941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological treatment for psychotic depression.
    Wijkstra J; Lijmer J; Burger H; Cipriani A; Geddes J; Nolen WA
    Cochrane Database Syst Rev; 2015 Jul; (7):CD004044. PubMed ID: 26225902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.